Search Results
Your search for ,kEY matches 7151 pages
Showing 6051 - 6100New Technology to Characterize Circulating Tumor Cells Suggests Better Treatment Decision-Making in Prostate Cancer
An early study showed that an experimental blood test (ie, “liquid biopsy”) that characterizes the phenotype and genomic characteristics of circulating tumor cells appears to have utility in personalizing treatment decisions for individual men with advanced prostate cancer.1 The assay—developed and ...
Three Industry Leaders Join the CancerLinQ Team
CancerLinQ LLC, a wholly owned nonprofit subsidiary of ASCO, has named three new members to its leadership team. David Dornstreich, Robert Merold, and Jennifer L. Wong recently joined CancerLinQ LLC and, in their various roles, will be utilizing their extensive strategic experience to fully realize ...
Bridging the Medical Gap in Long-Term Cancer Survivorship Care
Although more people than ever before are surviving cancer—there are currently 14.5 million cancer survivors, and that number is expected to climb to 19 million by 20241—they often experience long-lasting physical, emotional, and financial concerns related to the disease. To address the unmet...
2016 Head and Neck Cancer Symposium: Study Maps Distinct Molecular Signatures of HPV-Positive Throat Cancer by Smoking Status
Patients with throat cancer exposed to both human papillomavirus (HPV) and tobacco smoke demonstrate a pattern of mutations along several key cancer genes, according to research presented by Zevallos et al at the 2016 Multidisciplinary Head and Neck Cancer Symposium (Abstract 1). These distinct...
Expert Point of View: Bertram Wiedenmann, MD, PhD and Markus Moehler, MD, PhD
Commenting on the programmed cell death protein 1 (PD-1)/PD-1 ligand (PD-L1) antibodies in tumors with mismatch repair deficiency, Bertram Wiedenmann, MD, PhD, Professor of Internal Medicine and Gastroenterology, Universitätsmedizin Berlin, Germany, suggested, “The efficacy of pembrolizumab...
Inherited Genetic Variations That Lead to Severe Drug Toxicity in Pediatric Leukemia Discovered
An international research team has determined how inherited gene variations lead to severe drug toxicity that may threaten chances for a cure in children with leukemia. St. Jude Children’s Research Hospital scientists led the study, results of which set the stage to expand the use of a...
Norwegian Male Cancer Survivors Less Likely to Reproduce
A study of all Norwegian men born between 1965 and 1985 showed that male cancer survivors are less likely to have children than those without a cancer diagnosis. “These findings are important for male cancer survivors, seeing as we can identify groups at risk of having reproduction...
Study Examines Evolution of Cancer
A novel Yale University study answers age-old questions about how cancers spread by applying tools from evolutionary biology. The new insights will help scientists better understand the genetic origins of tumor metastases, and lead to more effective targets for treatment, said the researchers. The...
ACS/ASCO Breast Cancer Survivorship Care Guideline
The American Cancer Society (ACS) and ASCO have issued a Breast Cancer Survivorship Care guideline, published jointly in the Journal of Clinical Oncology and CA: A Cancer Journal for Clinicians. The guideline recommendations were formulated by a multidisciplinary expert work group and are based on...
ASCO Issues Policy Statement Calling for Improvements to Clinical Pathway Programs in Oncology
ASCO released a new policy statement with recommendations to ensure that clinical pathways in oncology promote—not hinder—the care of patients with cancer. Published by Zon et al in the Journal of Oncology Practice,1 the statement asserted that the way in which these treatment management tools in...
Hospira Foundation Donates $5 Million to the University of Chicago Medicine
The Hospira Foundation has donated $5 million to the University of Chicago Medicine to create the Hospira Foundation Professorship in Oncology. The Hospira Foundation Professor will be a key leader in advancing the University of Chicago Medicine’s cancer research objectives, which include...
James K.V. Willson, MD, Named Chief Scientific Officer of CPRIT
James K.V. Willson, MD, Associate Dean of Oncology Programs and Professor and Director of the Harold C. Simmons Comprehensive Cancer Center at University of Texas (UT) Southwestern Medical Center, has been named Chief Scientific Officer of the Cancer Prevention and Research Institute of Texas...
Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation in Older Patients With AML in First Remission
In a phase II study (CALGB 100103/Alliance/Blood and Marrow Transplant Clinical Trial Network 0502) reported in the Journal of Clinical Oncology,1 Steven M. Devine, MD, of The Ohio State University, Columbus, et al found that reduced-intensity conditioning allogeneic hematopoietic stem cell...
New Assay Detects Persistent Disease in Leukemia Patients Thought to Be in Remission
The outcomes of chronic myeloid leukemia (CML) have dramatically improved as the result of tyrosine kinase inhibitor treatment. Use of a tyrosine kinase inhibitor regimen can lower the blood CML biomarker to levels imperceptible by current detection methods. For patients in “molecular...
World Cancer Day 2016: We Can. I Can.
Cancer will kill more than 8 million people worldwide this year, which is equivalent to the entire population of New York. Half of these will be people of working age (30–69 years old). It has been estimated that the cost implications on world economies caused by cancer and the other...
ASCO Names Cancer Advance of the Year: Immunotherapy
At a Capitol Hill briefing today, ASCO announced immunotherapy as the top cancer advance of the year. Recent breakthroughs in immunotherapy—along with almost 60 other important cancer research advances—are described in ASCO's just-released report, Clinical Cancer Advances 2016: ASCO's...
Tamoxifen or Anastrozole for Ductal Carcinoma in Situ?
Ductal carcinoma in situ is a relatively benign form of breast cancer (stage 0), yet up to 10% of women with ductal carcinoma in situ will have a recurrence within 10 years. At present, there is no way to identify which women will recur, so standard treatment is lumpectomy plus radiation therapy....
Selected Abstracts From 2015 San Antonio Breast Cancer Symposium
The 2015 San Antonio Breast Cancer Symposium (SABCS), hosted by the American Association for Cancer Research, the Cancer Therapy & Research Center at The University of Texas Health Sciences Center at San Antonio, and Baylor College of Medicine, was held in December 2015. As has been true for...
Two Contenders for Second-Line Treatment of Advanced Renal Cell Carcinoma
Options for second-line therapy of advanced/metastatic renal cell carcinoma are expanding. Updates from the CheckMate 025 and METEOR trials presented at the 2016 Genitourinary Cancers Symposium solidify the value of both nivolumab (Opdivo, an immune checkpoint inhibitor) and cabozantinib...
Sparing Ovaries and Removing Fallopian Tubes May Cut Cancer Risk, but Few Have Procedure
During hysterectomies for noncancerous conditions, removing both fallopian tubes while keeping the ovaries may help protect against ovarian cancer and preserve hormonal levels, but few women receive this surgical option, according to a new study by Yale School of Medicine researchers. Published by ...
Afatinib Shows Clinical Benefit for Non–Small Cell Lung Cancer Patients With Brain Metastases
Non–small cell lung cancer (NSCLC) patients with common epidermal growth factor (EGFR) mutations and brain metastases showed improved progression-free survival and response from the EGFR tyrosine kinase inhibitor afatinib (Gilotrif) compared to standard platinum doublet chemotherapy....
Leora Horn, MD, MSc, on Targeted and Emerging Therapies for Metastatic NSCLC
Leora Horn, MD, MSc, of the Vanderbilt-Ingram Cancer Center, discusses the range of treatment options for people with lung cancer, including third generation inhibitors, and the key clinical trials studying alternatives for patients with acquired resistance.
Andrew Zelenetz, MD, PhD's Expert Analysis of Two Key Lymphoma Trials: FLASH and GADOLIN
Andrew Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses two important lymphoma trials presented at ASCO and his views on whether their results are indeed practice-changing (Abstract 8504 and LBA8502).
Derek Raghavan, MD, PhD: Roundup of Clinical Trial Results on Genitourinary Cancers
Derek Raghavan, MD, PhD, of the Levine Cancer Institute, gives his insights into key genitourinary cancer clinical trials presented at the 2015 ASCO Annual Meeting and his thoughts on where the research is headed.
Guneet Walia, PhD, on Central Issues in Lung Cancer Care
Guneet Walia, PhD, of the Lung Cancer Foundation, summarizes some key presentations: bridging the quality chasm, patients’ attitudes and physicians’ perceptions on maintenance therapy, and patient advocacy.
Joel E. Tepper, MD, on Radiotherapy in Liver and Pancreatic Cancers
Joel E. Tepper, MD, of the University of North Carolina School of Medicine, discusses the ways in which SBRT has changed radiotherapy, as demonstrated in key studies presented at this year's meeting on stereotactic body radiotherapy for liver metastases and hepatocellular carcinoma, and borderline...
Toni Choueiri, MD: Renal Cancer Update
Toni Choueiri, MD, of the Dana-Farber Cancer Institute, summarizes key points from a session he chaired on clear and non-clear cell renal cancer, including information on molecular genetics and its impact on treatment, how to treat patients with non-clear cell histology, and the best strategy for...
Evolution
Ten years ago, ASCO created the Journal of Oncology Practice to address a gap in the literature; there were no peer-reviewed journals dedicated to the practical issues of delivering quality oncology care. The original research and editorials published in JOP focus on care delivery topics such as...
Pieces of Grief
The ASCO Post is pleased to reproduce installments of the “Art of Oncology” as published previously in the Journal of Clinical Oncology (JCO). These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Ravi Salgia, MD, PhD, Joins City of Hope
Medical oncologist and researcher Ravi Salgia, MD, PhD, has joined City of Hope as Professor and Chair in the Department of Medical Oncology & Therapeutics Research. He will play a key leadership role in the expansion of clinical programs at City of Hope’s Duarte campus and in its clinics...
Study Reveals Potential Therapy Targets for Triple-Negative Breast Cancer
A multi-institutional international investigation led by scientists at The University of Texas MD Anderson Cancer Center, Houston, has revealed new information about how molecules called long noncoding RNAs (lncRNA) interact with HIF-1, a signaling pathway that is overexpressed in many cancers....
Ibrutinib in Relapsed Mantle Cell Lymphoma
Treatment of mantle cell lymphoma continues to evolve, both in the front-line and relapsed settings. Key advances include better use of established agents, such as the incorporation of high-dose cytarabine into initial induction regimens and application of rituximab (Rituxan)...
New Society of Breast Imaging Website Seeks to End Confusion Surrounding Mammography Screening
Breast cancer is the second-leading cause of cancer deaths among women in the United States. In 2015, according to the National Cancer Institute, 231,840 women were to be diagnosed with the disease and 40,290 were to die from it. The death rate is highest among women who are not screened regularly...
E-Cigarette Advertisements Reach Nearly 7 in 10 Middle and High School Students
About 7 in 10 middle and high school students—more than 18 million young people—see e-cigarette advertising in stores, online, in newspapers and magazines, or on television and in movies, according to a new Centers for Disease Control and Prevention (CDC) Vital Signs report. E-cigarette ads use...
ASCO University Announces New Immuno-Oncology Program
ASCO University has created a new multidisciplinary immunology program that provides a broad overview of immunobiology, as well as an in-depth focus on topics relevant to the practicing clinician, such as treatment, efficacy, monitoring, and management of immunobiologic agents. ASCO University’s...
Expert Point of View: Angela DeMichele, MD, and Melinda L. Telli, MD
The formal discussant for the CALGB 40603 and GeparSixto studies at the San Antonio Breast Cancer Symposium was Angela DeMichele, MD, Professor of Medicine and Miller Chair in Breast Cancer Excellence at the Perelman School of Medicine, University of Pennyslvania. “The key questions raised by these ...
PI3K Inhibitor Buparlisib Extends Progression-Free Survival in Advanced Breast Cancer
Addition of the oral investigational pan-PI3K inhibitor buparlisib to the endocrine agent fulvestrant (Faslodex) improved progression-free survival among postmenopausal women with advanced hormone receptor–positive/HER2-negative advanced breast cancer. “We are happy to announce that the phase III...
Expert Point of View: Kanti Rai, MD
In a separate interview, Kanti Rai, MD, of the Northwell Health System in New Hyde Park, New York, noted that venetoclax is one of several “exciting recent developments in this disease.” There is the Bruton tyrosine kinase inhibitor ibrutinib (Imbruvica), the PI3K inhibitor idelalisib (Zydelig),...
Venetoclax May Prove to Be Strong Weapon Against Poor-Prognosis Chronic Lymphocytic Leukemia
Venetoclax, the latest entry into the field of treatment of chronic lymphocytic leukemia (CLL), is a powerful investigational therapy that promises to fill an important niche: treatment of high-risk relapsed/refractory patients with deletions of 17p. Nearly 80% of patients with relapsed/refractory...
Idelalisib Improves Progression-Free Survival Over Bendamustine Plus Rituximab in Chronic Lymphocytic Leukemia
Idelalisib (Zydelig) combined with bendamustine (Bendeka, Treanda) plus rituximab (Rituxan) was superior to chemotherapy with bendamustine/rituximab plus placebo, reducing the risk of progressive disease and death while improving progression-free survival and overall survival in patients with...
Ado-Trastuzumab Emtansine Improved Overall Survival for Heavily Pretreated Patients With HER2-Positive Breast Cancer
Among patients with HER2-positive, metastatic breast cancer that had progressed despite treatment with two or more forms of HER2-targeted therapy (trastuzumab [Herceptin] and lapatinib [Tykerb]), median overall survival was increased for those treated with ado-trastuzumab emtansine (aka T-DM1...
Plasma-Based Test Identifies Impactful Mutations in BOLERO-2 Population
A plasma-based cell-free DNA test identified mutations in the estrogen receptor 1 gene (ESR1) in 30% of patients from the BOLERO-2 trial of everolimus (Afinitor) plus exemestane, and these mutations were correlated with survival. The results, which support the use of plasma as a source of...
Multiple Myeloma in 2015: A Year for the Record Books
Few malignancies have received as much attention, in the way of newly approved drugs, as multiple myeloma did in 2015. In November alone, 3 new agents were approved, bringing the total to 4 for the year as part of a record 7 approvals and to 16 regulatory approvals over the past 12 years. Speakers...
Study Shows Inferior Outcomes for African American Pediatric Lymphoma Patients
Researchers from Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have published a study showing that African American pediatric patients with Hodgkin lymphoma have inferior overall survival compared with their white and Hispanic peers. The study, published ...
UK Study Suggests Association Between Screen-Detected Ductal Carcinoma in Situ and Reduced Invasive Interval Breast Cancers
In a UK retrospective population-based study reported in The Lancet Oncology, Duffy et al found a significant inverse association between the detection of ductal carcinoma in situ in breast cancer screening and the incidence of invasive interval cancers diagnosed within 3 years after screening....
2016 GI Symposium: Tumor-Treating Fields Plus Chemotherapy May Be Safe as First-Line Treatment in Advanced Pancreatic Cancer
Novocure presented data from its ongoing phase II PANOVA clinical trial at the 2016 Gastrointestinal Cancers Symposium in San Francisco, showing that tumor-treating fields therapy plus first-line gemcitabine is tolerable and safe in patients with advanced pancreatic cancer. The data also suggest...
2016 GI Symposium: New Regimen for Locally Advanced Rectal Cancer as Effective as, but Less Toxic Than, Chemoradiation
Findings from a Polish phase III study point to an additional treatment option for patients with advanced rectal cancer. Patients who received short-course (5-day) radiation followed by consolidation chemotherapy before surgery achieved outcomes similar to those of patients treated with...
Inherited Genetic Markers May Predict Melanoma Survival and Help Plot Course of Disease
At NYU Langone Medical Center and its Laura and Isaac Perlmutter Cancer Center, researchers have discovered an inherited genetic marker that might provide clinicians with a personalized tool to gauge an individual’s survival and determine which patients require closer monitoring in the years...
Quality Improvement Projects Aim at Reducing Prescribing Errors for Chemotherapy
Two quality improvement projects described by Bryant-Bova in the Journal of Oncology Practiceresulted in reduced errors in prescribing intravenous and oral chemotherapy. A project at The University of Texas Medical Branch at Galveston outpatient infusion centers first identified 15 different types ...
New Method to Improve Preoperative Diagnosis of Ovarian Cancer Based on Ultrasound
In a landmark study, investigators from Europe proposed a new and simple method to assess the risk of malignancy of women with an adnexal mass. The method identified between 89% and 99% of patients with ovarian cancer using the results of ultrasound examination, which can be obtained in referral...
